Perrigo Company plc
PRGOHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 16, 2026
Scan Results
Daily timeframePerrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The $1.40B market capitalization puts PRGO squarely in small-cap range for its industry. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Market Cap
$1.40B
Beta
0.52
P/E (TTM)
—
P/E (Fwd)
4.30
EPS (TTM)
$-13.26
EPS (Fwd)
$2.36
ROE
-52.2%
ROA
2.1%
Cash
$357.2M
Total Debt
$3.83B
Free CF
$108.4M
52W Change
-62.5%
Annual Financials
Cash vs Debt
Perrigo Company plc carries $3.83B in total debt against $357.2M in cash reserves — debt is roughly 10.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $108.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -52.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.1% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $4.45B (2022) to $4.25B (2025).
With a beta below 0.7, Perrigo Company plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Perrigo Company plc carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PRGO.